cheap prom dresses prom dresses, cheap wedding dresses cheap wedding dresses, vintage wedding dresses vintage wedding dresses, cheap prom dresses cheap prom dresses for sale.
Top cheap prom dress cheap prom dresses, sexy wedding dresses sexy wedding dresses, prom dresses prom dresses, vintage prom dresses vintage peom dresses on sale.
首页| 关于依普比善| 品类动态| 学术天地| 临床讲座在线| PubMed文献速览| 在线交流| 联系我们
· “依普比善®醋酸奥曲肽注射液诚招全国代理商
· 依普比善®醋酸奥曲肽注射液市场现状及发展规划
· 依普比善®0.05毫克规格获SFDA批准生产
· 依普比善®(醋酸奥曲肽)0.3mg、0.05mg规格特价招商
· 招聘信息
· 0.05mg规格依普比善®变更有效期申请已报北京药监局
· 依普比善®试行标准转正申请进入复核阶段
· 依普比善®---醋酸奥曲肽注射液诚招部分地区地市级代理商
· 供应醋酸奥曲肽原料及水针制剂
· 0.05mg规格依普比善®变更有效期申请已获得北京药监局批准
· 招聘启事
· 依普比善®品牌知识问答
· 2008年消化、肿瘤专业国内学术会议消息
· 依普比善®推荐用法用量
· 依普比善®醋酸奥曲肽注射液与进口品的对比
· 依普比善®市场现状及最新发展规划
· 依普比善®与生长抑素类制剂的比较
· 依普比善®委托北京双鹭药业股份有限公司生产
· 依普比善®最新LOGO公布
· 依普比善®网站的问卷调查
· 生长抑素说明书
· 国家发改委关于生长抑素的最高定价
· 宝依普公司招聘启事
· 依普比善®礼品鼠标垫发放通知
· 《奥曲肽临床研究论文集》-5 发放通知
· 依普比善®“LOGO释义”
· 依普比善®产品图片
· 便签贴发放通知
· 《奥曲肽临床研究论文集》-6 发放通知
· 依普比善®礼品签字笔发放通知
· 依普比善®新包装投放市场通知
· 依普比善®更换新包装相关说明
· 依普比善®新旧包装对比说明
· 依普比善®网刊8及品牌礼品发放通知
· 奥曲肽、生长抑素统一定价药品最高零售限价
· 依普比善®再获商标注册证通告


Octreotide Long-Acting Repeatable Use Among Elderly Patients With Carcinoid Syndrome and Survival Outcomes


BACKGROUND: Octreotide long-acting repeatable (LAR) is indicated for the treatment of carcinoid syndrome and diarrhea related to VIPoma, and may delay tumor growth in patients with neuroendocrine tumors (NETs). To the authors’ knowledge, the pattern of octreotide LAR use in clinical practice and its impact on survival outcomes has not been well documented. METHODS: Using the Sur-veillance, Epidemiology, and End Results (SEER)-Medicare database, the authors identified patients with NET aged?65 years who were diagnosed between July 1999 and December 2007. Patients with US Food and Drug Administration-approved indications for octreotide LAR were identified from Medicare claims. Multivariate logistic regression was performed to ascertain factors associated with octreotide LAR use, whereas the Cox proportional hazards model was used to evaluate the impact of octreotide LAR on survival.

RESULTS: Among those with Food and Drug Administration-approved indications, 245 of 4848 patients with distant-stage disease (51%) and 81 of 807 patients with local/regional disease (10%) initiated treatment with octreotide LAR within 6 months of diagnosis. Multivariate logistic regression indicated that among those with distant-stage disease, older age (? 80 years vs 65-69 years) (odds ratio [OR], 0.43; 95% confidence interval [95% CI], 0.23-0.81), female sex (OR, 0.62; 95% CI, 0.40-0.97), and living in the South (vs Northeast) (OR, 0.36; 95% CI, 0.18-0.72) were associated with a lower likelihood of using octreotide LAR. The multivariate propor-tional hazards model showed that octreotide LAR provided a significant 5-year survival benefit for patients with distant-stage disease (hazards ratio, 0.61; P?.001), whereas this survival benefit was not shown for the patients with local/regional stage (hazards ratio, 0.88; P5.563). CONCLUSIONS: The results of this retrospective study suggest a possible survival benefit for the use of octreotide LAR in elderly patients with distant-stage NET with carcinoid syndrome. The results of the current study also suggest that octreotide
LAR is underused in this population despite recommended guidelines. Cancer 2014;000:000–000. VC 2014 American Cancer Society.

KEYWORDS: neuroendocrine tumors, malignant carcinoid syndrome, somatostatin analog, octreotide, health services for the aged, Surveillance, Epidemiology, and End Results (SEER)-Medicare.

客户服务 | 网站地图 | 在线留言 | 法律声明 | 友情链接 | 站内搜索 | 图片栏目 | 北京宝依普

版权所有 © 2005-2019 北京宝依普生物高技术有限责任公司 Beijing BIOEPO Biopharmaceutical Ltd.
电话:010-68210072 68289602 60216589 联系信箱